RICHMOND, VA--(Marketwire - Aug 28, 2012) - ALR Technologies Inc. (
ALR Technologies is now preparing for commercial production of the universal cable in conjunction with the national sales and distribution of their Health-e-Connect System.
Compatible with most digital glucose meters produced by the nation's top five manufacturers -- Abbott, Bayer, LifeScan (Johnson & Johnson), Nipro and Roche -- the Health-e-Connect system and universal data cable have already attracted the attention of frontline clinicians attending several recent national diabetes conventions. Endocrinologists, primary care physicians, and diabetes educators immediately saw the benefit of replacing multiple software platforms and data cables with one universal glucose monitoring platform and data upload cable.
"The universal cable is one of the cornerstones of the ALR Technologies system and we feel it gives us another competitive edge over others in the diabetes management space," says Sidney Chan, Chief Executive Officer and Chairman of ALR Technologies. "Managing multiple software platforms is not practical or cost-effective for providers, and it's not good for patients. Health-e-Connect eliminates the inefficiencies created by multiple platforms, giving providers more time to spend on direct patient care. It also gives providers the tools necessary to effectively manage entire patient populations, which is where the real opportunities lie in leveraging technology to coordinate care, improve patient outcomes, contain complications and reduce costs for widespread chronic diseases like diabetes."
Images comparing the universal cable with current clinical practice can be viewed at: www.alrt.com/assets/images/Cable_Comparison.pdf
About ALR Technologies Inc.
ALRT Health-e-Connect System ("System") is the principal product of the Company. HeC is a web based patient management platform for medical professionals to improve compliance and adherence of care plans of patients in their homes. The System is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com.
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate," "expect," "anticipate," "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange Commission.
Contact Information:
Public Relations:
ALR Technologies Inc.
804-554-3500 Ext. 704
e-mail: contact@alrt.com